Alterity Therapeutics Files Q1 FY25 Cash Flow Report
Ticker: PRNAF · Form: 6-K · Filed: Oct 31, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Oct 31, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: cash-flow, quarterly-report, filing-update
TL;DR
Alterity dropped its Q1 cash flow report, check the burn rate.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on October 31, 2024, incorporating by reference its Appendix 4C - Q1 FY25 Quarterly Cash Flow Report. This filing is part of ongoing registration statements on Form S-8 and Form F-3.
Why It Matters
This report provides investors with an update on Alterity's financial activities and cash burn for the first quarter of fiscal year 2025, crucial for assessing its operational runway.
Risk Assessment
Risk Level: medium — The filing is a routine quarterly cash flow report, but the company's development stage and reliance on future funding introduce inherent risks.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- Appendix 4C (document) — Incorporated Exhibit
- Q1 FY25 (date) — Reporting Period
- Form S-8 (document) — Registration Statement
- Form F-3 (document) — Registration Statement
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report the Appendix 4C - Q1 FY25 Quarterly Cash Flow Report and to incorporate it by reference into existing registration statements.
Which registration statements is this 6-K being incorporated into?
This 6-K is being incorporated into Alterity's Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What period does the Appendix 4C report cover?
The Appendix 4C report covers the first quarter of fiscal year 2025 (Q1 FY25).
What is Alterity Therapeutics Limited's principal executive office address?
Alterity Therapeutics Limited's principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics file annual reports under Form 20-F or Form 40-F?
Yes, Alterity Therapeutics indicates it files annual reports under Form 20-F.
Filing Stats: 193 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2024-10-31 08:48:12
Filing Documents
- ea0219341-6k_alterity.htm (6-K) — 14KB
- ea021934101ex99-1_alterity.htm (EX-99.1) — 111KB
- ex99-1_001.jpg (GRAPHIC) — 13KB
- 0001213900-24-092519.txt ( ) — 145KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Appendix 4C – Q1 FY25 Quarterly Cash Flow Report 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: October 31, 2024 2